The complaint centers on allegations that ARS Pharmaceuticals violated the Securities Exchange Act of 1934 by issuing false and misleading statements. Specifically, the firm claims the company recklessly disregarded risks concerning CVS Caremark’s integration of neffy into its formulary. Plaintiffs argue that management provided inaccurate guidance on insurance coverage timelines, which ultimately hampered the drug's commercialization and damaged investors when the true scope of the delays became public.

Shareholders who incurred losses during the specified period have until October 5, 2026, to seek appointment as lead plaintiff. While the class has not yet been certified, those affected may contact attorneys Brian Schall or David Schwartz in Los Angeles to discuss their legal standing. Participation in the litigation does not require an immediate appointment as lead plaintiff, and shareholders who take no action will remain absent class members by default.